Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IMI:TSE International Medical Innovations Inc. -- Ignore unavailable to you. Want to Upgrade?

To: thebeach who wrote (24)	3/12/2003 4:13:58 PM
From: gg cox	Read Replies (1) \| Respond to of 66

IMI receives SEC clearance to become registered issuer in U.S. Wednesday March 12, 12:08 pm ET TORONTO, March 12 /CNW/ - Predictive medicine company IMI International Medical Innovations Inc. (TSX:IMI - News) announced today that it has received clearance from the U.S. Securities and Exchange Commission (SEC) to become a registered issuer in the U.S., clearing the way for IMI shares to trade on a U.S. stock exchange. The SEC has declared IMI's Form 20-F registration statement effective, giving the company a class of securities registered with the SEC. IMI is continuing the application process to list its shares on the American Stock Exchange (AMEX). If IMI receives approval from the AMEX for the listing, the company will announce its ticker symbol and its first day of U.S. trading. "Listing our shares in the U.S. is a strategic priority because of the growing awareness and acceptance of predictive medicine," said Dr. Brent Norton, IMI President and CEO. "Both sides of our business - our cardiovascular products and our suite of cancer tests - are designed to meet recognized needs within the U.S. health care system, which we expect will result in heightened awareness of IMI in this large and vital market." About IMI IMI is a world leader in predictive medicine, dedicated to developing rapid, non-invasive tests for the early detection and monitoring of life-threatening diseases, particularly cardiovascular disease and cancer. IMI's lead product is a non-invasive skin test for coronary artery disease. IMI's cancer products in development include ColorectAlert(TM), a screening test for colorectal cancer, LungAlert(TM), a screening test for lung cancer, and a new test for breast cancer. For further information, please visit the company's web site at www.imimedical.com. This release contains forward-looking statements that reflect the company's current expectation regarding future events. The forward-looking statements involve risk and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, the approval by the AMEX of the company's listing application, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company's periodic filings. For further information Andrew Weir, Director, Communications Ron Hosking, VP and CFO, (416) 222-3449 x27, aweir@imimedical.com Richard Land, Karin Oloffson, Jaffoni & Collins Incorporated, (212) 835-8500 or imi@jcir.com biz.yahoo.com